Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity

Marylyn D. Ritchie*, David W. Haas, Alison A. Motsinger, John P. Donahue, Huso Erdem, Stephen Raffanti, Peter Rebeiro, Alfred L. George, Richard B. Kim, Jonathan L. Haines, Timothy R. Sterling

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

85 Scopus citations

Abstract

This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenzor nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→T (odds ratio, 0.254; P = .021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P < .001).

Original languageEnglish (US)
Pages (from-to)779-782
Number of pages4
JournalClinical Infectious Diseases
Volume43
Issue number6
DOIs
StatePublished - Sep 15 2006

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity'. Together they form a unique fingerprint.

Cite this